Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.

PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with radiation therapy works in treating young patients with Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Christine Mauz-Körholz
• Treatments: Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Liposomal doxorubicin; Prednisone; Procarbazine; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of classic Hodgkin's lymphoma (HL)

• Intermediate or advanced disease, including the following stages:

• Stage I

• Stage IIA, IIB, IIE, or IIBE

• Stage IIIA or IIIBE

• Stage IV

PATIENT CHARACTERISTICS:

• No other concurrent malignancies

• No severe concurrent diseases (e.g., immune deficiency syndrome)

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or radiotherapy

• Pre-phase therapy for large mediastinal tumor allowed